Literature DB >> 10571160

New pyrrole derivatives as antimycobacterial agents analogs of BM212.

M Biava1, R Fioravanti, G C Porretta, D Deidda, C Maullu, R Pompei.   

Abstract

During the course of our investigations in the field of azole antimicrobial agents, we have identified BM212 a pyrrole derivative with good in vitro activity against mycobacteria and candidae. These findings prompted us to prepare new pyrrole derivatives 2-6 in the hope of increasing the activity. The microbiological data showed interesting in vitro activity against Mycobacterium tuberculosis and atypical mycobacteria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571160     DOI: 10.1016/s0960-894x(99)00510-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

Review 1.  Mannich bases in medicinal chemistry and drug design.

Authors:  Gheorghe Roman
Journal:  Eur J Med Chem       Date:  2014-10-30       Impact factor: 6.514

Review 2.  Synthesis and structural activity relationship study of antitubercular carboxamides.

Authors:  D I Ugwu; B E Ezema; F U Eze; D I Ugwuja
Journal:  Int J Med Chem       Date:  2014-12-30

Review 3.  Recent approaches in the organocatalytic synthesis of pyrroles.

Authors:  Biplob Borah; Kartikey Dhar Dwivedi; L Raju Chowhan
Journal:  RSC Adv       Date:  2021-04-13       Impact factor: 3.361

4.  The multi-target aspect of an MmpL3 inhibitor: The BM212 series of compounds bind EthR2, a transcriptional regulator of ethionamide activation.

Authors:  Alice R Moorey; Alejandro Cabanillas; Sarah M Batt; Sonja Ghidelli-Disse; Beatriz Urones; Olalla Sanz; Joel Lelievre; Marcus Bantscheff; Liam R Cox; Gurdyal S Besra
Journal:  Cell Surf       Date:  2021-11-23

5.  Synthesis and evaluation of novel pyrroles and pyrrolopyrimidines as anti-hyperglycemic agents.

Authors:  M S Mohamed; S A Ali; D H A Abdelaziz; Samar S Fathallah
Journal:  Biomed Res Int       Date:  2014-06-26       Impact factor: 3.411

6.  MmpL3 as a Target for the Treatment of Drug-Resistant Nontuberculous Mycobacterial Infections.

Authors:  Wei Li; Amira Yazidi; Amitkumar N Pandya; Pooja Hegde; Weiwei Tong; Vinicius Calado Nogueira de Moura; E Jeffrey North; Jurgen Sygusch; Mary Jackson
Journal:  Front Microbiol       Date:  2018-07-10       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.